How to start a peptide telehealth business
The fastest-growing and most closely watched category in telehealth. The difference between a durable brand and a shut-down ad account is almost entirely catalog discipline and claims.
Key takeaways
- The commercial opportunity is real and so is the regulatory exposure. Catalog discipline decides which one you get.
- Only legally prescribable compounds, prescribed by a licensed provider and dispensed by a licensed compounding pharmacy.
- No research-use-only positioning anywhere. These are prescriptions or they are not sold.
- The primary risk is marketing, not medicine. FTC claim substantiation is where peptide brands actually get into trouble.
- Check-ins should gate the shipment, so there is no blind rebill on a scrutinised therapy.
Why this category attracts attention
Peptides sit at an awkward intersection: strong consumer demand, a wellness vocabulary that invites outcome claims, and compounds whose regulatory status varies and changes. That combination draws scrutiny from regulators and from ad platforms simultaneously.
The brands that last are not the ones with the most aggressive catalog. They are the ones whose catalog, workflow and copy would all survive being read closely by someone unsympathetic.
Catalog discipline is the whole game
The single decision that most determines outcomes is what appears in your catalog. Legally prescribable compounds, prepared by licensed compounding pharmacies, prescribed for an appropriate patient by a licensed provider.
Anything positioned as research-use-only is a different activity with a different risk profile, and mixing the two contaminates the legitimate side of the business. If a compound cannot be prescribed and dispensed properly, it should not be in the storefront.
Provider review with no auto-approve path
Every order should be a clinical decision made by a clinician licensed in the patient's state, who can decline. In a category this scrutinised, a workflow that can be skipped is a workflow that will eventually be examined.
That means no automatic approval tier, no pre-approved product that ships on payment, and a real audit trail: intake version, provider decision, prescription event and pharmacy transmission, logged per patient and queryable.
The risk is in the copy
This is the part operators underestimate most consistently. FTC claim substantiation exposure in peptides typically exceeds the clinical risk, because the clinical workflow is comparatively easy to get right and the marketing is comparatively easy to get wrong.
Outcome claims, before-and-after framing, longevity and performance language, and testimonials all carry substantiation requirements. What your storefront promises matters at least as much as what your providers prescribe.
- Substantiate outcome claims or do not make them.
- Describe compounded preparations accurately rather than implying FDA approval.
- Keep testimonials representative and disclosed.
- Have someone who is not the copywriter review the storefront against FTC and ad-platform standards before launch.
Refills, gated
The typical cadence is a four-week review after the initial fill, then twelve-week refill cycles. Each renewal should be approved by the reviewing provider after a check-in reporting tolerance and response.
A blind rebill that ships without review is both a clinical shortcut and the exact pattern that looks worst under examination. Gating the shipment on the check-in costs a small amount of conversion and removes a category of risk entirely.
Compliant rails, and LegitScript at $0
PharmaBro supports only legally prescribable compounds through licensed compounding pharmacies, requires provider review on every order with no auto-approve path, and gates refills on a provider-approved check-in.
LegitScript certification is included at $0 and filed in parallel with your build, landing in 7 to 14 days. In a category where ad accounts are the first thing to go, certification plus disciplined claims is what keeps you operating.
Conclusion
Peptides reward discipline more than speed. The catalog decision, the provider review and the claims review are the three controls that determine whether this is a durable business or a temporary one.
Get those right and the demand takes care of itself. Get the copy wrong and the clinical workflow will not save you.
Frequently asked questions
Are peptides legal to sell through telehealth?
Legally prescribable compounds, prescribed by a licensed provider for an appropriate patient and dispensed by a licensed compounding pharmacy, yes. Research-use-only positioning is a different activity with a different risk profile and should not be mixed into a prescription business.
What is the biggest risk in a peptide brand?
Marketing claims. FTC substantiation exposure typically exceeds the clinical risk, because the workflow is comparatively easy to get right and the copy is comparatively easy to get wrong. Have the storefront reviewed by someone other than the person who wrote it.
Can I advertise a peptide brand?
With LegitScript certification, yes, on the major platforms. Given the scrutiny this category attracts, certification combined with substantiated claims is what keeps an ad account alive rather than merely getting it approved.
How do peptide refills work?
Typically a four-week review after the initial fill, then twelve-week cycles, with the provider approving each renewal after a check-in. The next fill should not ship on a blind rebill.
Priya RaghunathanHead of Compliance Operations
Handles LegitScript, HIPAA posture, MSO structuring and state coverage. Writes the parts of this blog that operators wish someone had told them before they signed.